Caxton Associates LLP Makes New Investment in RxSight, Inc. $RXST

Caxton Associates LLP acquired a new stake in RxSight, Inc. (NASDAQ:RXST) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 70,279 shares of the company’s stock, valued at approximately $914,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Petrus Trust Company LTA raised its stake in RxSight by 5.0% during the 1st quarter. Petrus Trust Company LTA now owns 19,651 shares of the company’s stock valued at $496,000 after purchasing an additional 938 shares during the last quarter. State of Wyoming raised its position in shares of RxSight by 91.5% during the first quarter. State of Wyoming now owns 2,062 shares of the company’s stock valued at $52,000 after buying an additional 985 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of RxSight by 6.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,861 shares of the company’s stock valued at $552,000 after buying an additional 1,232 shares during the period. Legal & General Group Plc grew its position in RxSight by 5.0% during the second quarter. Legal & General Group Plc now owns 44,574 shares of the company’s stock worth $579,000 after buying an additional 2,121 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in RxSight during the second quarter worth about $28,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

RxSight Stock Down 0.8%

Shares of RXST stock opened at $12.52 on Tuesday. The firm has a fifty day moving average of $9.83 and a 200-day moving average of $10.03. RxSight, Inc. has a 12-month low of $6.32 and a 12-month high of $39.37. The company has a market capitalization of $514.82 million, a price-to-earnings ratio of -14.23 and a beta of 1.13.

RxSight (NASDAQ:RXST) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.15. The company had revenue of $30.34 million during the quarter, compared to analysts’ expectations of $25.63 million. RxSight had a negative return on equity of 12.82% and a negative net margin of 25.15%.RxSight’s revenue for the quarter was down 31.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.16) earnings per share. On average, equities analysts expect that RxSight, Inc. will post -0.7 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on RXST. Needham & Company LLC upped their target price on RxSight from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Wells Fargo & Company increased their target price on RxSight from $9.00 to $10.00 and gave the stock an “equal weight” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. lifted their target price on RxSight from $8.00 to $9.00 and gave the company an “underweight” rating in a research note on Thursday, November 6th. Zacks Research raised shares of RxSight from a “strong sell” rating to a “hold” rating in a research note on Monday, September 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of RxSight in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, RxSight has an average rating of “Reduce” and a consensus price target of $9.67.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.